Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from <scp>CALGB</scp> 80203 (Alliance)
Ace J. Hatch(Duke Medical Center), Andrew B. Nixon(Duke University), Alan P. Venook(University of California, San Francisco), Federico Innocenti(AbbVie (United States)), Herbert I. Hurwitz(Duke Medical Center), Mark D. Starr(Duke Medical Center), Donna Niedzwiecki(Duke University), Herbert Pang(Duke University), Daniel L. Bowers(Duke Medical Center), Chen Jiang, John C. Brady(Duke Medical Center), Alexander B. Sibley(Duke University), Jingquan Jia(Duke Medical Center), Kouros Owzar(Duke University)
Cited by 20
Related Papers
Hepatobiliary Cancers
|Journal of the National Comprehensive Cancer Network|2009|2.3k
Liver Transplantation for Hepatocellular Carcinoma: Expansion of the Tumor Size Limits Does Not Adversely Impact Survival
|Hepatology|2001|2.3k
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|998